Roche Re-Opens Bank Account: Firm Again A Creditor After Genentech Sale
Executive Summary
Roche is once again a net creditor following its most recent offering of Genentech shares, CFO Henri Meier told the company's annual earnings conference March 30 in Basel, Switzerland.
You may also be interested in...
Biotech Licensing Often More Cost-Effective Than In-House R&D For Pharma
Large pharmaceutical manufacturers are entering into more early stage licensing deals with biotechs because such deals are often more cost-effective than conducting in-house research, Bayer VP-Business Development Chris Seaton said
Biotech Licensing Often More Cost-Effective Than In-House R&D For Pharma
Large pharmaceutical manufacturers are entering into more early stage licensing deals with biotechs because such deals are often more cost-effective than conducting in-house research, Bayer VP-Business Development Chris Seaton said
Avastin Launch Unlikely To Affect Xeloda Sales, Roche Says
Early launch data from Genentech's Avastin indicate the oncologic will not affect Xeloda sales, Roche Worldwide Pharmaceuticals Head William Burns said